Description

IGF-1 LR3 (Receptor Grade) 1 mg is a highly purified, research-focused form of the synthetic peptide IGF-1 LR3. It is a long-acting analogue of insulin-like growth factor 1 (IGF-1), a naturally occurring peptide hormone essential for cellular growth, tissue repair, and metabolic regulation.

The “receptor-grade” label indicates that this form is optimized for experimental studies requiring high bioactivity and minimal impurities. It is intended strictly for research use and is not approved as a pharmaceutical or therapeutic product.

What Is IGF-1 LR3 ?

IGF-1 LR3 is a modified version of endogenous IGF-1 with structural changes that:

• Extend its half-life in the body

• Reduce binding to IGF-binding proteins

These modifications allow IGF-1 LR3 to remain active longer and act more efficiently at IGF-1 receptors on cells. The 1 mg receptor-grade formulation emphasizes maximum purity and potency for research applications.

How IGF-1 LR3 (Receptor Grade) Works

IGF-1 LR3 binds directly to IGF-1 receptors on target cells. Activation of these receptors initiates intracellular signaling pathways that:

• Promote protein synthesis

• Stimulate cell proliferation

• Support tissue repair and regeneration

• Enhance nutrient uptake and metabolism

Unlike growth hormone–releasing peptides, IGF-1 LR3 acts directly at the cellular level rather than indirectly stimulating GH production, making it more potent in its effects on target tissues.

Potential Areas of Research Interest

IGF-1 LR3 (Receptor Grade) 1 mg is commonly studied in laboratory and preclinical research, including:

• Muscle growth and satellite cell activation

• Recovery from tissue damage or injury

• Connective tissue, cartilage, and bone regeneration

• Cellular metabolism and nutrient signaling

• IGF-1 receptor binding dynamics and activation mechanisms

Its receptor-grade purity ensures reproducible results in receptor-focused experiments.

Research Status and Evidence

While IGF-1 itself is extensively studied, IGF-1 LR3 (Receptor Grade) is primarily used in preclinical and in vitro research. Human clinical data are extremely limited, and long-term effects, dosing protocols, and safety have not been established.

This form is particularly valuable for studies examining precise molecular mechanisms and receptor-level interactions.